- Home
- BRDG vs IMMP Comparison
BRDG vs IMMP Comparison
Compare BRDG & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRDG
- IMMP
- Stock Information
- Founded
- BRDG 2009
- IMMP 1987
- Country
- BRDG United States
- IMMP Australia
- Employees
- BRDG N/A
- IMMP N/A
- Industry
- BRDG Investment Managers
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- BRDG Finance
- IMMP Health Care
- Exchange
- BRDG Nasdaq
- IMMP Nasdaq
- Market Cap
- BRDG 323.7M
- IMMP 304.0M
- IPO Year
- BRDG 2021
- IMMP N/A
- Fundamental
- Price
- BRDG $9.44
- IMMP $1.78
- Analyst Decision
- BRDG Hold
- IMMP Buy
- Analyst Count
- BRDG 6
- IMMP 2
- Target Price
- BRDG $10.67
- IMMP $8.50
- AVG Volume (30 Days)
- BRDG 654.5K
- IMMP 82.5K
- Earning Date
- BRDG 05-07-2025
- IMMP 03-25-2025
- Dividend Yield
- BRDG 4.88%
- IMMP N/A
- EPS Growth
- BRDG N/A
- IMMP N/A
- EPS
- BRDG 0.25
- IMMP N/A
- Revenue
- BRDG $419,220,000.00
- IMMP $3,019,249.00
- Revenue This Year
- BRDG N/A
- IMMP N/A
- Revenue Next Year
- BRDG $26.25
- IMMP $20.28
- P/E Ratio
- BRDG $38.29
- IMMP N/A
- Revenue Growth
- BRDG 61.35
- IMMP 24.11
- 52 Week Low
- BRDG $6.18
- IMMP $1.65
- 52 Week High
- BRDG $11.69
- IMMP $3.34
- Technical
- Relative Strength Index (RSI)
- BRDG 54.40
- IMMP 41.69
- Support Level
- BRDG $9.14
- IMMP $1.65
- Resistance Level
- BRDG $9.71
- IMMP $1.88
- Average True Range (ATR)
- BRDG 0.40
- IMMP 0.10
- MACD
- BRDG -0.08
- IMMP -0.01
- Stochastic Oscillator
- BRDG 34.17
- IMMP 41.94
About BRDG Bridge Investment Group Holdings Inc.
Bridge Investment Group Holdings Inc is a vertically integrated investment manager, diversified across specialized asset classes. The company combines its nationwide operating platform with dedicated teams of investment professionals focused on various specialized and synergistic investment platforms, including real estate, credit, renewable energy, and secondaries strategies. Its broad range of products and vertically integrated structure allow it to capture new market opportunities and serve investors with various investment objectives. The company operates Its business in a single segment, alternative investment management, diversified across specialized and synergistic investment platforms.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.